Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Sensory stimulation enhances TFRC-targeted apoferritin nanoparticle delivery of ginsenoside Rb1 to promote endothelial protection and stroke recovery.

Created on 30 Sep 2026

Authors

Qi Wang, Rui Ouyang, Fangbo Hu, Jie Feng, Guangyu Jia, Xiaolong Tang, Yajing Cui, Jingjing Jiang, Yuheng Li, Lei Wu, Shiyong Li, Ye Wang

Published in

Nanomedicine : nanotechnology, biology, and medicine. Pages 103031. Sep 29, 2026. Epub Sep 29, 2026.

Abstract

Effective treatment of ischemic stroke requires improved perfusion and drug delivery to the ischemic penumbra. We investigated whether sensory stimulation could enhance cerebral blood flow and improve delivery of an apoferritin (Aft)-based ginsenoside Rb1 nanodelivery system (Aft@Rb1). Sensory stimulation increased blood flow in the barrel cortex after cerebral ischemia-reperfusion (I/R). By exploiting increased transferrin receptor 1 expression in cerebrovascular endothelial cells, Aft@Rb1 achieved targeted delivery to ischemic tissue. In mice with cerebral I/R, sensory stimulation combined with Aft@Rb1 increased local Rb1 accumulation, reduced blood-brain barrier disruption and infarct area, and improved neurological recovery. These findings indicate that sensory stimulation can enhance local perfusion and nanodrug delivery, providing a potential combined therapeutic strategy for ischemic brain injury.

PMID:
42810654
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement